/
SGHT
$5.84+$0.15 (+2.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$309.6M
54M shares
52-week range
$3.11 – $9.24
45% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.86%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.66
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $23.3M | $27.6M | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Cost of revenue | $2.3M | $6.5M | $9.2M | $8.6M | $12.4M | $11.9M | $11.6M | $10.7M |
| Gross profit | $5.2M | $16.8M | $18.4M | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M |
| Gross margin | 69.0% | 72.0% | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| R&D | $5.4M | $8.1M | $8.9M | $15.6M | $22.9M | $17.6M | $18.0M | $14.6M |
| Operating income | −$14.3M | −$24.0M | −$32.2M | −$51.5M | −$84.0M | −$57.3M | −$50.5M | −$37.1M |
| EBITDA | −$14.2M | −$23.5M | −$31.7M | −$57.2M | −$80.5M | −$49.4M | −$45.9M | −$32.8M |
| Net income | −$14.3M | −$25.9M | −$34.7M | −$63.0M | −$86.2M | −$55.5M | −$51.5M | −$38.4M |
| Net margin | -189.8% | -110.8% | -125.5% | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| EPS (diluted) | -0.44 | -0.77 | -0.74 | -1.33 | -1.80 | -1.14 | -1.03 | -0.74 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $86M | $-0.78 | $-0.99–$-0.60 | 3 |
| 2027 | $96M | $-0.67 | $-0.93–$-0.38 | 3 |
| 2028 | $104M | $-0.56 | $-0.71–$-0.31 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.77
Price
$5.84
Implied downside
-70%
Peer comparison
Sight Sciences, Inc. Common Stock
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
www.sightsciences.com- Employees
- 186
- IPO / List date
- Jul 15, 2021
- HQ
- MENLO PARK, CA
Held by traders on TradeandTell
No one on the platform currently holds SGHT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 293,358 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SGHT yet.
